Growth Metrics

Summit Therapeutics (SMMT) Net Cash Flow (2016 - 2026)

Summit Therapeutics filings provide 13 years of Net Cash Flow readings, the most recent being -$118.7 million for Q1 2026.

  • Quarterly Net Cash Flow fell 211.36% to -$118.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$105.1 million through Mar 2026, down 169.96% year-over-year, with the annual reading at $120.3 million for FY2025, 256.11% up from the prior year.
  • Net Cash Flow hit -$118.7 million in Q1 2026 for Summit Therapeutics, down from -$13.3 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $525.3 million in Q4 2022 and bottomed at -$578.1 million in Q1 2023.
  • Average Net Cash Flow over 5 years is $2.1 million, with a median of -$9.8 million recorded in 2024.
  • The largest annual shift saw Net Cash Flow surged 6634.72% in 2022 before it crashed 10024.15% in 2023.
  • Summit Therapeutics' Net Cash Flow stood at $525.3 million in 2022, then tumbled by 90.98% to $47.4 million in 2023, then tumbled by 76.36% to $11.2 million in 2024, then plummeted by 218.55% to -$13.3 million in 2025, then tumbled by 794.47% to -$118.7 million in 2026.
  • Per Business Quant, the three most recent readings for SMMT's Net Cash Flow are -$118.7 million (Q1 2026), -$13.3 million (Q4 2025), and -$59.3 million (Q3 2025).